X0306 4 2021-06-21 1 0001840574 Verve Therapeutics, Inc. VERV 0001769012 ARCH Venture Partners X, LLC 8755 WEST HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631 0 0 1 0 0001757011 ARCH Venture Fund X, L.P. 8755 WEST HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631 0 0 1 0 0001757017 ARCH Venture Fund X Overage, L.P. 8755 WEST HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631 0 0 1 0 0001782583 ARCH Venture Partners X, L.P. 8755 WEST HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631 0 0 1 0 0001768905 ARCH Venture Partners X Overage, L.P. 8755 WEST HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631 0 0 1 0 0001219039 CRANDELL KEITH 8755 WEST HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631 0 0 1 0 0001219042 NELSEN ROBERT 8755 WEST HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631 0 0 1 0 0001569248 Burow Kristina 8755 WEST HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631 0 0 1 0 0001229592 GILLIS STEVEN 8755 WEST HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631 0 0 1 0 Common Stock, par value $0.001 2021-06-21 4 C 0 1254404 A 1254404 I ARCH Venture Fund X, L.P. Common Stock, par value $0.001 2021-06-21 4 C 0 1254405 A 1254405 I ARCH Venture Fund X Overage, L.P. Series A Convertible Preferred Stock 2021-06-21 4 C 0 7107024 D Common Stock 767538 0 I See Footnotes Series A Convertible Preferred Stock 2021-06-21 4 C 0 7107023 D Common Stock 767538 0 I See Footnotes Series A-2 Convertible Preferred Stock 2021-06-21 4 C 0 4508144 D Common Stock 486866 0 I See Footnotes Series A-2 Convertible Preferred Stock 2021-06-21 4 C 0 4508146 D Common Stock 486867 0 I See Footnotes Represents shares held directly by ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH X. Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage. ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Robert Nelsen, Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein. The shares of Issuer's Preferred Stock converted into shares of Issuer's Common Stock, for no additional consideration, on a 1-for-9.2595 basis immediately prior to the consummation of Issuer's initial public offering. The expiration date is not relevant to the conversion of these securities. /s/ ARCH Venture Fund X, L.P., By: ARCH Venture Partners X, L.P., its General Partner, By: ARCH Venture Partners X, LLC, its General Partner, By: Mark McDonnell, attorney in-fact 2021-06-23 /s/ ARCH Venture Fund X Overage, L.P., By: ARCH Venture Partners X Overage, L.P., its General Partner, By: ARCH Venture Partners X, LLC, its General Partner, By: Mark McDonnell, attorney in-fact 2021-06-23 /s/ ARCH Venture Partners X, L.P., By: ARCH Venture Partners X, LLC, its General Partner, By: Mark McDonnell, attorney in-fact 2021-06-23 /s/ ARCH Venture Partners X Overage, L.P., By: ARCH Venture Partners X, LLC, its General Partner, By: Mark McDonnell, attorney in-fact 2021-06-23 /s/ ARCH Venture Partners X, LLC, By: Mark McDonnell, attorney in-fact 2021-06-23 /s/ Keith Crandell, By: Mark McDonnell, attorney in-fact 2021-06-23 /s/ Robert Nelsen, By: Mark McDonnell, attorney in-fact 2021-06-23 /s/ Kristina Burow, By: Mark McDonnell, attorney in-fact 2021-06-23 /s/ Steven Gillis, By: Mark McDonnell, attorney in-fact 2021-06-23